JPRN-UMIN000036096暂停未知
Complication after TLIP block - Complication after TLIP block
适应症
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Case with no TLIP block
研究者
相似试验
进行中（未招募）
1 期
Study of Tislelizumab in Patients with Relapsed or Refractory Hodgkin LymphomaRefractory/relapse Hodgkin LymphomaMedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2019-002105-22-ESBeiGene Ltd.100
进行中（未招募）
1 期
Study of Tislelizumab in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2019-002105-22-FRYSARC100
进行中（未招募）
1 期
Study to evaluate Trilaciclib Administered with Chemotherapy and Avelumab Maintenance Therapy in Patients with bladder cancerntreated, Locally Advanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2021-000205-24-ESG1 Therapeutics, Inc.90
进行中（未招募）
1 期
Study to evaluate Trilaciclib Administered with Chemotherapy and Avelumab Maintenance Therapy in Patients with bladder cancerntreated, Locally Advanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2021-000205-24-HUG1 Therapeutics, Inc.90
进行中（未招募）
1 期
Study to evaluate Trilaciclib Administered with Chemotherapy and Avelumab Maintenance Therapy in Patients with bladder cancerntreated, Locally Advanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2021-000205-24-FRG1 Therapeutics, Inc.90